Regeneron Pharmaceuticals (REGN) 324.31 $REGN
Watch For Today's Momo Momentum Stock: Regeneron Pharmaceuticals (REGN)
at The Street - Fri Aug 01, 9:17AM CDT
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a momo momentum candidate
Sanofi Beats on Q2 Earnings, View Up on Strong Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 8:10AM CDT
Sanofi (SNY) reported second quarter 2014 business earnings of 80 cents per American Depositary Share.
BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 4:00PM CDT
BioMarin (BMRN) reported a narrower-than-expected loss aided by higher revenues.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
BioMarin reports sale of rare pediatric disease priority review voucher programme for USD67.5m
M2 - Thu Jul 31, 5:34AM CDT
Biopharmaceuticals company BioMarin Pharmaceutical (NasdaqGS:BMRN) reported on Wednesday the sale of the Rare Pediatric Disease Priority Review Voucher (PRV) for USD67.5m from Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals.
'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific
at The Street - Thu Jul 31, 5:00AM CDT
Cramer isn't crazy about Nimble Storage but thinks Pitney Bowes stock can go higher.
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 6:00PM CDT
Regeneron Pharmaceuticals, Inc.'s (REGN) eye drug Eylea received FDA approval for a third indication: the treatment of diabetic macular edema.
Stocks End Mixed; Akamai Falls, Yelp Rises After Hours
at Investor's Business Daily - Wed Jul 30, 4:00PM CDT
Initial enthusiasm over a stronger-than-expected reading on second-quarter gross domestic product faded Wednesday as major averages ended with a mixed performance. The Nasdaq outperformed again. In the after-hours session, Akamai Technologies (AKAM)...
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 5.80% Yesterday
Comtex SmarTrend(R) - Wed Jul 30, 3:44PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $315.00 to a high of $336.94. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $307.66 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BioMarin Sells Priority Review Voucher for $67.5 Million
GlobeNewswire - Wed Jul 30, 3:01PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has sold the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in February of this year. The Company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. BioMarin was awarded the voucher when it received approval of VIMIZIM, a new biological product for patients with Mucopolysaccharidosis type IVA, also known as Morquio A syndrome. BioMarin received $67.5 million from Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals, Inc., in exchange for the voucher.
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
PR Newswire - Wed Jul 30, 3:01PM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the Companies intend to use a U.S. Food and Drug Administration (FDA) rare pediatric disease priority review voucher in connection with the Biologics License Application (BLA) submission for alirocumab. The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited 6-month review from the filing date instead of the standard 10-month review.
Amgen Restructuring Plan, Q2 Earnings Send Stock Up
at Investor's Business Daily - Wed Jul 30, 10:20AM CDT
Amgen (AMGN) was up more than 5%, near 129, in early trading in the stock market today as analysts approved of big-cap biotech's earnings beat and restructuring plans announced late Tuesday. Earlier, Amgen stock touched a new high above 131. Amgen's...
Jim Cramer's Mad Dash: Good News for Regeneron
at The Street - Wed Jul 30, 9:45AM CDT
TheStreet's Jim Cramer says Regeneron has developed a breakthrough cholesterol drug while also receiving positive Phase III results for another treatment.
Stocks Thrash Out A Mixed Open; Buffalo Wild Wings Crumples
at Investor's Business Daily - Wed Jul 30, 9:31AM CDT
Stocks quickly trimmed their opening gains Wednesday, turning narrowly mixed in early trading. The Nasdaq defended a 0.4% gain. The S&P 500 held on to a fractional advance. The Dow Jones industrial average dipped 0.1%. Small caps outpaced the market,...
Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
PR Newswire - Wed Jul 30, 7:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).
Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
PR Newswire - Wed Jul 30, 7:00AM CDT
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)
PR Newswire - Tue Jul 29, 5:32PM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of EYLEA in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. Although EYLEA may be dosed as frequently as 2 mg every 4 weeks, additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks.
Watch For Today's Momo Momentum Stock: Regeneron Pharmaceuticals (REGN)
at The Street - Fri Aug 01, 9:17AM CDT
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a momo momentum candidate
Sanofi Beats on Q2 Earnings, View Up on Strong Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 8:10AM CDT
Sanofi (SNY) reported second quarter 2014 business earnings of 80 cents per American Depositary Share.
BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 4:00PM CDT
BioMarin (BMRN) reported a narrower-than-expected loss aided by higher revenues.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
BioMarin reports sale of rare pediatric disease priority review voucher programme for USD67.5m
M2 - Thu Jul 31, 5:34AM CDT
Biopharmaceuticals company BioMarin Pharmaceutical (NasdaqGS:BMRN) reported on Wednesday the sale of the Rare Pediatric Disease Priority Review Voucher (PRV) for USD67.5m from Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals.
'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific
at The Street - Thu Jul 31, 5:00AM CDT
Cramer isn't crazy about Nimble Storage but thinks Pitney Bowes stock can go higher.
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 6:00PM CDT
Regeneron Pharmaceuticals, Inc.'s (REGN) eye drug Eylea received FDA approval for a third indication: the treatment of diabetic macular edema.
Stocks End Mixed; Akamai Falls, Yelp Rises After Hours
at Investor's Business Daily - Wed Jul 30, 4:00PM CDT
Initial enthusiasm over a stronger-than-expected reading on second-quarter gross domestic product faded Wednesday as major averages ended with a mixed performance. The Nasdaq outperformed again. In the after-hours session, Akamai Technologies (AKAM)...
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 5.80% Yesterday
Comtex SmarTrend(R) - Wed Jul 30, 3:44PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $315.00 to a high of $336.94. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $307.66 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BioMarin Sells Priority Review Voucher for $67.5 Million
GlobeNewswire - Wed Jul 30, 3:01PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has sold the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in February of this year. The Company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. BioMarin was awarded the voucher when it received approval of VIMIZIM, a new biological product for patients with Mucopolysaccharidosis type IVA, also known as Morquio A syndrome. BioMarin received $67.5 million from Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals, Inc., in exchange for the voucher.
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
PR Newswire - Wed Jul 30, 3:01PM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the Companies intend to use a U.S. Food and Drug Administration (FDA) rare pediatric disease priority review voucher in connection with the Biologics License Application (BLA) submission for alirocumab. The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited 6-month review from the filing date instead of the standard 10-month review.
Amgen Restructuring Plan, Q2 Earnings Send Stock Up
at Investor's Business Daily - Wed Jul 30, 10:20AM CDT
Amgen (AMGN) was up more than 5%, near 129, in early trading in the stock market today as analysts approved of big-cap biotech's earnings beat and restructuring plans announced late Tuesday. Earlier, Amgen stock touched a new high above 131. Amgen's...
Jim Cramer's Mad Dash: Good News for Regeneron
at The Street - Wed Jul 30, 9:45AM CDT
TheStreet's Jim Cramer says Regeneron has developed a breakthrough cholesterol drug while also receiving positive Phase III results for another treatment.
Stocks Thrash Out A Mixed Open; Buffalo Wild Wings Crumples
at Investor's Business Daily - Wed Jul 30, 9:31AM CDT
Stocks quickly trimmed their opening gains Wednesday, turning narrowly mixed in early trading. The Nasdaq defended a 0.4% gain. The S&P 500 held on to a fractional advance. The Dow Jones industrial average dipped 0.1%. Small caps outpaced the market,...
Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
PR Newswire - Wed Jul 30, 7:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).
Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
PR Newswire - Wed Jul 30, 7:00AM CDT
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)
PR Newswire - Tue Jul 29, 5:32PM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of EYLEA in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. Although EYLEA may be dosed as frequently as 2 mg every 4 weeks, additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks.
